Meeting Coverage

Meeting Coverage

video

CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma Patients

Antonio Palumbo, MD, discusses the “unprecedented” results of the CASTOR Trial, a plenary, late-breaking abstract at ASCO 2016.
video

TOURMALINE-MM3 and 4: Ixazomib as Maintenance Therapy in Myeloma Patients

Sagar Lonial, MD, provides an update on TOURMALINE-MM3 and 4, which are looking at the role of ixazomib as maintenance therapy in patients with...
video

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

Tara L. Lin, MD, shares the initial findings from a trial evaluating venetoclax with standard low-dose cytarabine in older patients with acute myeloid leukemia...
video

Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

Andrew M. Evens, DO, MSc, on the early results of ECOG-ACRIN E2408 trial, which found that adding bortezomib to standard bendamustine-rituximab treatment increases the...
video

Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma

Amrita Y. Krishnan, MD, shares the promising preliminary results from a phase I/II study of the triplet regimen ixazomib, pomalidomide, and dexamethasone in patients...
video

Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL

Noelle V. Frey, MD, discusses the challenges of balancing the promises of chimeric antigen receptor T-cell therapy with its side effects in patients with...
video

David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line...

With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate...

Investigational Drug BLU-285 Shows Tolerable Safety, Early Clinical Activity in Patients With Advanced Systemic...

Data from an ongoing phase I trial of BLU-285, an oral inhibitor of KIT D816V, in patients with advanced systemic mastocytosis (SM) suggest that...

Age, Comorbidity, Time on Chemotherapy Predict Increases in Hospitalizations, ER Visits Among CLL Patients

Researchers identified several risk factors leading to greater health-care resource use, including age, comorbidity burden, presence of adverse events, and duration of therapy, in...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.